🔬 Third-party verified peptides · Free Express Post over $200 CAD
Pantheon Peptides
Fat Loss5 cited studies

AOD9604

Modified hGH C-terminal fragment — selective lipolytic without GH-axis effects.

Also known as: AOD-9604 · AOD 9604
SummaryMechanismDosingSafetyStudies
Research use only — not for human consumption.

What it is

AOD9604 is a synthetic peptide derived from a modified fragment of human growth hormone (hGH 177-191) that targets fat metabolism. It stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis without affecting blood glucose or insulin levels. Research has also explored it for cartilage repair and joint health.

Mechanism of action

Mimics the lipolytic C-terminus of hGH but lacks the receptor-binding domain responsible for IGF-1 induction and glucose effects. Stimulates β3-adrenergic receptor signalling and downstream lipase activation, with effects independent of the canonical GH/IGF-1 axis.

Half-life: Short — minutes to hours; daily dosing typical.

Evidence summary

Preclinical lipid-metabolism work (Heffernan 2000-2001) supports the lipolytic profile. A 2013 human safety/tolerability study in healthy volunteers reported a favorable profile. Joint-tissue work (2015) suggests potential for cartilage support.

Typical dosing protocols

Typical dose
300–600 mcg
Frequency
Once daily
Cycle length
12 weeks
  • 300–600 mcg subcutaneous, once daily (typical research protocol)
  • Cycles 8–12 weeks; combine with caloric deficit and resistance training
  • Often paired with GH secretagogues for body-composition focus

Side effects & safety

  • Generally well-tolerated in published studies
  • Mild injection-site reactions reported
  • No long-term human safety data

Cited studies

  1. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research.
    Read source ↗
  2. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity.
    Read source ↗
  3. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology.
    Read source ↗
  4. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism.
    Read source ↗
  5. (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science.
    Read source ↗
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.